Agios Pharmaceuticals, Inc. - Wutah pendapatan triwulanan AGIO

Agios Pharmaceuticals (AGIO) - logo korporat

Agios Pharmaceuticals (AGIO) is currently restructuring its business model following the divestment of oncology assets in an effort to diversify its portfolio. The company is recognized as a pioneer in cellular metabolism, having earned the loyalty of patients with rare pathologies. Relative quarterly revenue growth reflects sales dynamics, where 330.30 indicates the value of this parameter. The growth potential of the stock is supported by the expansion of Pyrukynd, incoming royalties, and a significant liquidity reserve.

AGIO Tingkat wutah dodolan sajrone kuartal Agios Pharmaceuticals Inc (04.07.2022 - 20.11.2026)

Ringkesan rincian data analitis Agios Pharmaceuticals, Inc. (AGIO)

- kuotasi saiki lan rata-rata prakiraan nilai:
- indikator dhuwit lan arus kas:
Analisis komprehensif perusahaan:agios.com (AGIO)
Produk sing diprodhuksi agios.com

For Agios Pharmaceuticals (AGIO), revenue growth reflects the effective commercialization of Pyrukynd and the influx of royalties, allowing for a comparison between actual business scaling rates and market expectations. By analyzing the dynamics of quarterly sales changes, an investor sees a smoothed curve of daily fundamental data recalculations, which helps identify the gap between price euphoria and slowing cash flows, thereby preventing overpayment for the asset.

Pesaing Agios Pharmaceuticals

ASND - Wutah pendapatan kuartal marang kuartal|MDGL: Wutah pendapatan kuartal marang kuartal|CORT: Wutah pendapatan triwulanan|RYTM - Tingkat wutah dodolan sajrone kuartal|Wutah pendapatan kuartal marang kuartal Akero Corp|Metsera Therapeutics (MTSR) - Tingkat wutah dodolan sajrone kuartal|Wutah pendapatan kuartal marang kuartal moonlaketx.com (MLTX)|Wutah dodolan triwulanan Crinetics Pharmaceuticals CRNX|Wutah pendapatan kuartal marang kuartal NewAmsterdam Pharma N.V. NAMS|Tingkat wutah dodolan sajrone kuartal Soleno Therapeutics Inc (SLNO)|FOLD - Wutah pendapatan kuartal marang kuartal|ETNB: Wutah pendapatan kuartal marang kuartal|Structure Therapeutics (GPCR) - Wutah pendapatan kuartal marang kuartal|Wutah dodolan triwulanan MiMedx Group, Inc.|Wutah pendapatan kuartal marang kuartal Rezolute Bio|Lexicon Pharmaceuticals, Inc. (LXRX) - Tingkat wutah dodolan sajrone kuartal|Wutah pendapatan triwulanan MBX|Wutah dodolan triwulanan Altimmune, Inc. ALT|Wutah pendapatan triwulanan AARD (Aardvark Pharma)|Sagimet Biosciences Inc. (SGMT) - Tingkat wutah pendapatan sajrone kuartal|BIOA: Wutah dodolan triwulanan|Tambahing pendapatan triwulanan BMEA (Biomea Fusion)|QNCX (quincetx.com) - Wutah dodolan triwulanan|Fractyl - Tambahing pendapatan triwulanan|VTVT (vTv Therapeutics Inc) - Wutah pendapatan triwulanan|Agape ATP - Dinamika pendapatan kuartal marang kuartal|Wutah dodolan triwulanan PLUR (Pluri Inc)|Tingkat wutah dodolan sajrone kuartal Synlogic Inc.|Wutah pendapatan kuartal marang kuartal Lipocine Inc. LPCN|Matinas BioPharma (MTNB) - Tingkat wutah pendapatan sajrone kuartal|Spruce Biosciences Inc. - Wutah pendapatan triwulanan|Tingkat wutah dodolan sajrone kuartal Galecto, Inc. GLTO|Carmell Therapeutics (CTCX) - Wutah pendapatan kuartal marang kuartal|Lumos Pharma - Tambahing pendapatan triwulanan|ONVO (Organovo Corp) - Wutah pendapatan triwulanan|Radius Pharmaceuticals (RDUS) - Tingkat wutah dodolan sajrone kuartal